ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1645

A sex-modified association between Perfluoroalkyl and Polyfluoroalkyl Substances (PFAS) blood concentration and prevalent arthritis among young and middle-aged US adults

Queeneth Edwards1, Samuel Mbadu1, Jhy-Charm Soo2 and Jian Zhang2, 1Georgia Southern University, Statesboro, GA, 2Georgia Southern University, statesboro

Meeting: ACR Convergence 2025

Keywords: Arthritis, Infectious, immunology, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1633–1649) ARP Posters II: ARP Epidemiology & Public Health

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Perfluoroalkyl and Polyfluoroalkyl Substances (PFAS) (PFAS), including Perfluorooctanoic acid (PFOA) and Perfluorooctane sulfonate (PFOS), are persistent environmental contaminants that may influence inflammatory joint diseases by altering immune function and promoting chronic inflammation. While studies on PFAS and rheumatoid arthritis risk have yielded mixed results, likely due to methodological flaws like misapplied odds ratios. We estimated the marginal effect of PFAS exposure on arthritis diagnosis among young and middle-aged U.S. adults.

Methods: We analyzed data from 3,984 participants aged 20-49 years in the 2005–2020 nationally representative survey, using surplus sera collected for cotinine testing. Analyses were limited to the five PFAS measured continuously during this period among eligible participants: 2-(N-methyl-PFOSA) acetic acid (Me-PFOSA-AcOH), Perfluorodecanoic acid (PFDA), Perfluorohexane sulfonic acid (PFHxS), Perfluorononanoic acid (PFNA), and Perfluoroundecanoic acid (PFUA).Marginal effects on prevalence of doctor-diagnosed arthritis were estimated by comparing high (4th quarter) and moderate (2nd–3rd quarter) PFAS exposure to low (1st quarter) level exposure. Potential confounders adjusted for included age (modeled as a continuous variable), race/ethnicity, family income, history of major chronic diseases (including cardiovascular diseases, diabetes, and cancer), and body mass index.

Results: The overall prevalence of arthritis was 9.80% (standard error = 0.57%), with 401 cases identified. Among men, neither a significant association nor a clear pattern was observed across the five PFAS analysed. Specifically, the prevalence of arthritis was 8.94% (95% CI: 5.82%, 12.06%), 8.25% (6.14%, 10.36%), and 5.56% (1.87%, 9.26%) for those with high, moderate, and low concentrations of Me-PFOSA-AcOH, respectively. The adjusted marginal effect (ME) for high Me-PFOSA-AcOH was 2.68 (95% CI: -2.16, 7.53) relative to low PFAS concentration, while for high PFUnDA it was -1.85 (95% CI: -6.13, 2.43).
In contrast, a clear pattern of association emerged among women, with statistically significant findings for some PFAS. Among women, the prevalence of arthritis was 12.58% (95% CI: 9.26%, 15.91%), 11.78% (95% CI: 9.60%, 13.95%), and 7.06% (95% CI: 3.57%, 10.55%) for high, moderate, and low concentrations of Me-PFOSA-AcOH, respectively. The adjusted MEs were 5.60% (95% CI: 0.47%, 10.72%) for those with high levels and 4.13% (95% CI: -0.69%, 8.95%) for those with moderate levels compared to women with low levels, with a significant linear trend (p = 0.033). Similar statistically significant associations were observed for PFDA and PFUnDA, whereas the associations for PFHxS and PFNA did not reach statistical significance.

Conclusion: High levels of PFAS were associated with an increased prevalence of arthritis among women, but not among men. The distinct susceptibility suggests that differences in hormonal or metabolic responses to these persistent chemicals may underlie the association. These findings warrant further longitudinal and mechanistic studies

Supporting image 1Note: 95%CI=95% confidence interval; NHANES=The National Health and Nutrition Examination Survey; p(L)=p value for linear trend, and p(Q), p value for quadratic trend, PFAS=Perfluoroalkyl substances.

1. The case numbers of arthritis.

2. Estimated with fixed effect. The marginal effect indicates the predicted change in the percentage of adults with a high-level body weight or height associated with a high level of PFAS compared to a low level, holding the covariates at their mean value.

3. The p-value for the marginal effect against the reference level (difference > 0).


Disclosures: Q. Edwards: None; S. Mbadu: None; J. Soo: None; J. Zhang: None.

To cite this abstract in AMA style:

Edwards Q, Mbadu S, Soo J, Zhang J. A sex-modified association between Perfluoroalkyl and Polyfluoroalkyl Substances (PFAS) blood concentration and prevalent arthritis among young and middle-aged US adults [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/a-sex-modified-association-between-perfluoroalkyl-and-polyfluoroalkyl-substances-pfas-blood-concentration-and-prevalent-arthritis-among-young-and-middle-aged-us-adults/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-sex-modified-association-between-perfluoroalkyl-and-polyfluoroalkyl-substances-pfas-blood-concentration-and-prevalent-arthritis-among-young-and-middle-aged-us-adults/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology